Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Revenue (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Revenue for 17 consecutive years, with $434.9 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 1.74% to $434.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 1.53% year-over-year, with the annual reading at $1.6 billion for FY2025, 1.53% up from the prior year.
  • Revenue hit $434.9 million in Q4 2025 for Integra Lifesciences Holdings, up from $402.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $442.6 million in Q4 2024 to a low of $360.1 million in Q1 2021.
  • Historically, Revenue has averaged $394.4 million across 5 years, with a median of $388.4 million in 2021.
  • Biggest five-year swings in Revenue: soared 50.77% in 2021 and later decreased 4.16% in 2023.
  • Year by year, Revenue stood at $405.5 million in 2021, then dropped by 1.85% to $398.0 million in 2022, then dropped by 0.25% to $397.0 million in 2023, then increased by 11.49% to $442.6 million in 2024, then fell by 1.74% to $434.9 million in 2025.
  • Business Quant data shows Revenue for IART at $434.9 million in Q4 2025, $402.1 million in Q3 2025, and $415.6 million in Q2 2025.